Tavneos is a drug owned by Chemocentryx Inc. It is protected by 4 US drug patents filed from 2021 to 2024 out of which none have expired yet. Tavneos's patents have been open to challenges since 07 October, 2025. Based on its patents and exclusivities, its generic launch date is estimated to be May 29, 2041. Details of Tavneos's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11603356 | Amorphous form of a complement component C5a receptor |
May, 2041
(15 years from now) | Active |
| US8445515 | C5aR antagonists |
Feb, 2031
(5 years from now) | Active |
| US8906938 | C5aR antagonists |
Dec, 2029
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11951214 | Capsule formulations |
Nov, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Tavneos's patents.
Latest Legal Activities on Tavneos's Patents
Given below is the list of recent legal activities going on the following patents of Tavneos.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification
Critical | 16 Apr, 2024 | US11951214 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 16 Apr, 2024 | US11951214 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 12 Apr, 2024 | US8445515 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 12 Apr, 2024 | US8906938 |
| Email Notification
Critical | 12 Apr, 2024 | US8445515 |
| Email Notification
Critical | 12 Apr, 2024 | US8906938 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951214 |
| Email Notification
Critical | 09 Apr, 2024 | US11951214 |
FDA has granted several exclusivities to Tavneos. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Tavneos, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Tavneos.
Exclusivity Information
Tavneos holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Tavneos's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Tavneos is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tavneos's family patents as well as insights into
ongoing legal events
on those patents.
Tavneos's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tavneos's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 29, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tavneos Generics:
There are no approved generic versions for Tavneos as of now.
About Tavneos
Tavneos is a drug owned by Chemocentryx Inc. It is used for treating severe active ANCA-associated vasculitis in adult patients in combination with standard therapy. Tavneos uses Avacopan as an active ingredient. Tavneos was launched by Chemocentryx in 2021.
Approval Date:
Tavneos was approved by FDA for market use on 07 October, 2021.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Tavneos is 07 October, 2021, its NCE-1 date is estimated to be 07 October, 2025.
Active Ingredient:
Tavneos uses Avacopan as the active ingredient. Check out other Drugs and Companies using Avacopan ingredient
Treatment:
Tavneos is used for treating severe active ANCA-associated vasculitis in adult patients in combination with standard therapy.
Dosage:
Tavneos is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG | CAPSULE | Prescription | ORAL |